Global and United States Familial Amyloid Polyneuropathy Market Report & Forecast 2023-2028

Report ID: 1718306 | Published Date: Jan 2025 | No. of Page: 86 | Base Year: 2024 | Rating: 5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Familial Amyloid Polyneuropathy Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million) Introduction
    1.2 Global Familial Amyloid Polyneuropathy Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Familial Amyloid Polyneuropathy Market Size for the Year 2017-2028
        1.2.2 Global Familial Amyloid Polyneuropathy Market Size for the Year 2017-2028
    1.3 Familial Amyloid Polyneuropathy Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.3.1 The Market Share of United States Familial Amyloid Polyneuropathy in Global, 2017 VS 2022 VS 2028
        1.3.2 The Growth Rate of Familial Amyloid Polyneuropathy Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.4 Familial Amyloid Polyneuropathy Market Dynamics
        1.4.1 Familial Amyloid Polyneuropathy Industry Trends
        1.4.2 Familial Amyloid Polyneuropathy Market Drivers
        1.4.3 Familial Amyloid Polyneuropathy Market Challenges
        1.4.4 Familial Amyloid Polyneuropathy Market Restraints
    1.5 Study Objectives
    1.6 Years Considered
2 Familial Amyloid Polyneuropathy by Type
    2.1 Familial Amyloid Polyneuropathy Market Segment by Type
        2.1.1 FAP-I
        2.1.2 FAP-II
        2.1.3 FAP-III
        2.1.4 FAP-IV
    2.2 Global Familial Amyloid Polyneuropathy Market Size by Type (2017, 2022 & 2028)
    2.3 Global Familial Amyloid Polyneuropathy Market Size by Type (2017-2028)
    2.4 United States Familial Amyloid Polyneuropathy Market Size by Type (2017, 2022 & 2028)
    2.5 United States Familial Amyloid Polyneuropathy Market Size by Type (2017-2028)
3 Familial Amyloid Polyneuropathy by Application
    3.1 Familial Amyloid Polyneuropathy Market Segment by Application
        3.1.1 Hospitals and Clinics
        3.1.2 Others
    3.2 Global Familial Amyloid Polyneuropathy Market Size by Application (2017, 2022 & 2028)
    3.3 Global Familial Amyloid Polyneuropathy Market Size by Application (2017-2028)
    3.4 United States Familial Amyloid Polyneuropathy Market Size by Application (2017, 2022 & 2028)
    3.5 United States Familial Amyloid Polyneuropathy Market Size by Application (2017-2028)
4 Global Familial Amyloid Polyneuropathy Competitor Landscape by Company
    4.1 Global Familial Amyloid Polyneuropathy Market Size by Company
        4.1.1 Top Global Familial Amyloid Polyneuropathy Companies Ranked by Revenue (2021)
        4.1.2 Global Familial Amyloid Polyneuropathy Revenue by Player (2017-2022)
    4.2 Global Familial Amyloid Polyneuropathy Concentration Ratio (CR)
        4.2.1 Familial Amyloid Polyneuropathy Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Companies of Familial Amyloid Polyneuropathy in 2021
        4.2.3 Global Familial Amyloid Polyneuropathy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Familial Amyloid Polyneuropathy Headquarters, Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million) Type
        4.3.1 Global Familial Amyloid Polyneuropathy Headquarters and Area Served
        4.3.2 Global Familial Amyloid Polyneuropathy Companies Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million) Type
        4.3.3 Date of International Companies Enter into Familial Amyloid Polyneuropathy Market
    4.4 Companies Mergers & Acquisitions, Expansion Plans
    4.5 United States Familial Amyloid Polyneuropathy Market Size by Company
        4.5.1 Top Familial Amyloid Polyneuropathy Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Familial Amyloid Polyneuropathy Revenue by Players (2020, 2021 & 2022)
5 Global Familial Amyloid Polyneuropathy Market Size by Region
    5.1 Global Familial Amyloid Polyneuropathy Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Familial Amyloid Polyneuropathy Market Size by Region (2017-2028)
        5.2.1 Global Familial Amyloid Polyneuropathy Market Size by Region: 2017-2022
        5.2.2 Global Familial Amyloid Polyneuropathy Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Familial Amyloid Polyneuropathy Market Size YoY Growth 2017-2028
        6.1.2 North America Familial Amyloid Polyneuropathy Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 U.S.
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Familial Amyloid Polyneuropathy Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Familial Amyloid Polyneuropathy Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
        6.2.12 Philippines
    6.3 Europe
        6.3.1 Europe Familial Amyloid Polyneuropathy Market Size YoY Growth 2017-2028
        6.3.2 Europe Familial Amyloid Polyneuropathy Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Familial Amyloid Polyneuropathy Market Size YoY Growth 2017-2028
        6.4.2 Latin America Familial Amyloid Polyneuropathy Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Familial Amyloid Polyneuropathy Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Familial Amyloid Polyneuropathy Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE
7 Company Profiles
    7.1 Pfizer
        7.1.1 Pfizer Company Details
        7.1.2 Pfizer Business Overview
        7.1.3 Pfizer Familial Amyloid Polyneuropathy Introduction
        7.1.4 Pfizer Revenue in Familial Amyloid Polyneuropathy Business (2017-2022)
        7.1.5 Pfizer Recent Development
    7.2 GSK
        7.2.1 GSK Company Details
        7.2.2 GSK Business Overview
        7.2.3 GSK Familial Amyloid Polyneuropathy Introduction
        7.2.4 GSK Revenue in Familial Amyloid Polyneuropathy Business (2017-2022)
        7.2.5 GSK Recent Development
    7.3 Ionis
        7.3.1 Ionis Company Details
        7.3.2 Ionis Business Overview
        7.3.3 Ionis Familial Amyloid Polyneuropathy Introduction
        7.3.4 Ionis Revenue in Familial Amyloid Polyneuropathy Business (2017-2022)
        7.3.5 Ionis Recent Development
    7.4 Alnylam
        7.4.1 Alnylam Company Details
        7.4.2 Alnylam Business Overview
        7.4.3 Alnylam Familial Amyloid Polyneuropathy Introduction
        7.4.4 Alnylam Revenue in Familial Amyloid Polyneuropathy Business (2017-2022)
        7.4.5 Alnylam Recent Development
    7.5 Corino Therapeutics
        7.5.1 Corino Therapeutics Company Details
        7.5.2 Corino Therapeutics Business Overview
        7.5.3 Corino Therapeutics Familial Amyloid Polyneuropathy Introduction
        7.5.4 Corino Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2017-2022)
        7.5.5 Corino Therapeutics Recent Development
    7.6 Proclara Bioscience
        7.6.1 Proclara Bioscience Company Details
        7.6.2 Proclara Bioscience Business Overview
        7.6.3 Proclara Bioscience Familial Amyloid Polyneuropathy Introduction
        7.6.4 Proclara Bioscience Revenue in Familial Amyloid Polyneuropathy Business (2017-2022)
        7.6.5 Proclara Bioscience Recent Development
    7.7 Arcturus Therapeutics
        7.7.1 Arcturus Therapeutics Company Details
        7.7.2 Arcturus Therapeutics Business Overview
        7.7.3 Arcturus Therapeutics Familial Amyloid Polyneuropathy Introduction
        7.7.4 Arcturus Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2017-2022)
        7.7.5 Arcturus Therapeutics Recent Development
8 Research Findings and Conclusion
9 Appendix
    9.1 Research Methodology
        9.1.1 Methodology/Research Approach
        9.1.2 Data Source
    9.2 Author Details
    9.3 Disclaimer

List of Tables
    Table 1. Familial Amyloid Polyneuropathy Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Familial Amyloid Polyneuropathy Market Trends
    Table 3. Familial Amyloid Polyneuropathy Market Drivers
    Table 4. Familial Amyloid Polyneuropathy Market Challenges
    Table 5. Familial Amyloid Polyneuropathy Market Restraints
    Table 6. Global Familial Amyloid Polyneuropathy Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Familial Amyloid Polyneuropathy Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Familial Amyloid Polyneuropathy Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Familial Amyloid Polyneuropathy Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Familial Amyloid Polyneuropathy Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Familial Amyloid Polyneuropathy Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Familial Amyloid Polyneuropathy Revenue Share by Player, 2017-2022
    Table 13. Global Familial Amyloid Polyneuropathy Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Familial Amyloid Polyneuropathy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy as of 2021)
    Table 15. Top Players of Familial Amyloid Polyneuropathy in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Familial Amyloid Polyneuropathy Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Familial Amyloid Polyneuropathy Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Familial Amyloid Polyneuropathy Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Familial Amyloid Polyneuropathy Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Familial Amyloid Polyneuropathy Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Familial Amyloid Polyneuropathy Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Familial Amyloid Polyneuropathy Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Familial Amyloid Polyneuropathy Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Familial Amyloid Polyneuropathy Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Familial Amyloid Polyneuropathy Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Familial Amyloid Polyneuropathy Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Familial Amyloid Polyneuropathy Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Pfizer Company Details
    Table 31. Pfizer Business Overview
    Table 32. Pfizer Familial Amyloid Polyneuropathy Product
    Table 33. Pfizer Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million)
    Table 34. Pfizer Recent Development
    Table 35. GSK Company Details
    Table 36. GSK Business Overview
    Table 37. GSK Familial Amyloid Polyneuropathy Product
    Table 38. GSK Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million)
    Table 39. GSK Recent Development
    Table 40. Ionis Company Details
    Table 41. Ionis Business Overview
    Table 42. Ionis Familial Amyloid Polyneuropathy Product
    Table 43. Ionis Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million)
    Table 44. Ionis Recent Development
    Table 45. Alnylam Company Details
    Table 46. Alnylam Business Overview
    Table 47. Alnylam Familial Amyloid Polyneuropathy Product
    Table 48. Alnylam Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million)
    Table 49. Alnylam Recent Development
    Table 50. Corino Therapeutics Company Details
    Table 51. Corino Therapeutics Business Overview
    Table 52. Corino Therapeutics Familial Amyloid Polyneuropathy Product
    Table 53. Corino Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million)
    Table 54. Corino Therapeutics Recent Development
    Table 55. Proclara Bioscience Company Details
    Table 56. Proclara Bioscience Business Overview
    Table 57. Proclara Bioscience Familial Amyloid Polyneuropathy Product
    Table 58. Proclara Bioscience Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million)
    Table 59. Proclara Bioscience Recent Development
    Table 60. Arcturus Therapeutics Company Details
    Table 61. Arcturus Therapeutics Business Overview
    Table 62. Arcturus Therapeutics Familial Amyloid Polyneuropathy Product
    Table 63. Arcturus Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2017-2022) & (US$ Million)
    Table 64. Arcturus Therapeutics Recent Development
    Table 65. Research Programs/Design for This Report
    Table 66. Key Data Information from Secondary Sources
    Table 67. Key Data Information from Primary Sources
List of Figures
    Figure 1. Familial Amyloid Polyneuropathy Product Picture
    Figure 2. Global Familial Amyloid Polyneuropathy Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Familial Amyloid Polyneuropathy Market Size 2017-2028 (US$ Million)
    Figure 4. United States Familial Amyloid Polyneuropathy Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Familial Amyloid Polyneuropathy Market Size 2017-2028 (US$ Million)
    Figure 6. United States Familial Amyloid Polyneuropathy Market Share in Global 2017-2028
    Figure 7. Familial Amyloid Polyneuropathy Report Years Considered
    Figure 8. Product Picture of FAP-I
    Figure 9. Product Picture of FAP-II
    Figure 10. Product Picture of FAP-III
    Figure 11. Product Picture of FAP-IV
    Figure 12. Global Familial Amyloid Polyneuropathy Market Share by Type in 2022 & 2028
    Figure 13. Global Familial Amyloid Polyneuropathy Market Size by Type (2017-2028) & (US$ Million)
    Figure 14. Global Familial Amyloid Polyneuropathy Market Share by Type (2017-2028)
    Figure 15. United States Familial Amyloid Polyneuropathy Market Share by Type in 2022 & 2028
    Figure 16. United States Familial Amyloid Polyneuropathy Market Size by Type (2017-2028) & (US$ Million)
    Figure 17. United States Familial Amyloid Polyneuropathy Market Share by Type (2017-2028)
    Figure 18. Product Picture of Hospitals and Clinics
    Figure 19. Product Picture of Others
    Figure 20. Global Familial Amyloid Polyneuropathy Market Share by Application in 2022 & 2028
    Figure 21. Global Familial Amyloid Polyneuropathy Market Size by Application (2017-2028) & (US$ Million)
    Figure 22. Global Familial Amyloid Polyneuropathy Market Share by Application (2017-2028)
    Figure 23. United States Familial Amyloid Polyneuropathy Market Share by Application in 2022 & 2028
    Figure 24. United States Familial Amyloid Polyneuropathy Market Size by Application (2017-2028) & (US$ Million)
    Figure 25. United States Familial Amyloid Polyneuropathy Market Share by Application (2017-2028)
    Figure 26. North America Familial Amyloid Polyneuropathy Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 27. U.S. Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 28. Canada Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 29. Europe Familial Amyloid Polyneuropathy Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 30. Germany Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 31. France Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. U.K. Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. Italy Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. Russia Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Asia-Pacific Familial Amyloid Polyneuropathy Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 36. China Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. Japan Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. South Korea Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. India Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. Australia Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Taiwan Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Indonesia Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Thailand Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Malaysia Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Philippines Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Latin America Familial Amyloid Polyneuropathy Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 47. Mexico Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Brazil Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Argentina Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Middle East & Africa Familial Amyloid Polyneuropathy Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 51. Turkey Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Saudi Arabia Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. UAE Familial Amyloid Polyneuropathy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Pfizer Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2017-2022)
    Figure 55. GSK Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2017-2022)
    Figure 56. Ionis Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2017-2022)
    Figure 57. Alnylam Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2017-2022)
    Figure 58. Corino Therapeutics Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2017-2022)
    Figure 59. Proclara Bioscience Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2017-2022)
    Figure 60. Arcturus Therapeutics Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2017-2022)
    Figure 61. Bottom-up and Top-down Approaches for This Report
    Figure 62. Data Triangulation
    Figure 63. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Pfizer
GSK
Ionis
Alnylam
Corino Therapeutics
Proclara Bioscience
Arcturus Therapeutics
Frequently Asked Questions
Familial Amyloid Polyneuropathy report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Familial Amyloid Polyneuropathy report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Familial Amyloid Polyneuropathy report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports